Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 April 23, 2021 at 11:00 AM UTC
Internal link ProQR Announces Participation in Upcoming Kempen Life Sciences Conference April 22, 2021 at 11:00 AM UTC
Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 April 13, 2021 at 08:15 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares April 05, 2021 at 08:15 PM UTC
Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 April 02, 2021 at 08:15 PM UTC
Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares March 31, 2021 at 02:25 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares March 30, 2021 at 08:05 PM UTC
Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials March 24, 2021 at 11:00 AM UTC
Internal link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome March 17, 2021 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference March 02, 2021 at 09:30 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results February 25, 2021 at 12:00 PM UTC
Internal link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome February 16, 2021 at 09:30 PM UTC
Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 January 07, 2021 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 November 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference October 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals October 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals October 29, 2018 at 11:33 AM UTC